Literature DB >> 10430398

K-ras mutations in gastric stump carcinomas and in carcinomas from the non-operated stomach.

B P van Rees1, A Musler, E Caspers, P Drillenburg, M E Craanen, W Polkowski, D Chibowski, G J Offerhaus.   

Abstract

BACKGROUND/AIMS: Partial gastrectomy is a well-established pre-malignant condition. It is postulated that in the gastric stump an accelerated neoplastic process takes place, similar to that of (intestinal type) adenocarcinoma from the non-operated stomach. K-ras codon 12 mutation is one of the most frequent oncogenic alterations in human solid neoplasms. It is rare in conventional gastric carcinoma and has not been studied in gastric stump carcinoma. The aim of this study was to compare the prevalence of K-ras codon 12 point mutations in gastric stump carcinomas with those in conventional carcinomas from the non-operated stomach.
METHODOLOGY: Twenty-four gastric stump carcinomas were compared with 26 conventional gastric carcinomas. Stage, histology, and demographics were comparable in both groups. Mutations in codon 12 of the K-ras gene were examined with a polymerase chain reaction (PCR)-based method and subsequent dot blot hybridization with mutation-specific probes. The results of Helicobacter pylori infection, Epstein-Barr virus infection and p53 immunohistochemistry were partially known from a previous study.
RESULTS: In one of the gastric stump carcinomas as well as in one of the conventional gastric carcinomas a K-ras codon 12 point mutation was found. p53 immunohistochemistry results were comparable in both groups. Interestingly, Helicobacter pylori infection rate and Epstein-Barr virus in situ hybridization for EBER1, as previously studied, appeared were significantly different in the two groups.
CONCLUSIONS: K-ras codon 12 point mutations are rare in both gastric stump carcinomas and conventional gastric carcinomas. This supports the postulated hypothesis that the pathways of carcinogenesis in both gastric stump carcinoma and conventional gastric carcinoma share common features. However, these groups differ in infection rate of Helicobacter pylori and of Epstein-Barr virus, which suggests that some neoplastic stimuli differ as well.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430398

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  5 in total

1.  Incidence and clinical features of endoscopic ulcers developing after gastrectomy.

Authors:  Woo Chul Chung; Eun Jung Jeon; Kang-Moon Lee; Chang Nyol Paik; Sung Hoon Jung; Jung Hwan Oh; Ji Hyun Kim; Kyong-Hwa Jun; Hyung Min Chin
Journal:  World J Gastroenterol       Date:  2012-07-07       Impact factor: 5.742

Review 2.  Does remnant gastric cancer really differ from primary gastric cancer? A systematic review of the literature by the Task Force of Japanese Gastric Cancer Association.

Authors:  Hideaki Shimada; Takeo Fukagawa; Yoshio Haga; Koji Oba
Journal:  Gastric Cancer       Date:  2015-12-14       Impact factor: 7.370

3.  Frequent loss of RUNX3 gene expression in remnant stomach cancer and adjacent mucosa with special reference to topography.

Authors:  Y Nakase; C Sakakura; K Miyagawa; S Kin; K Fukuda; A Yanagisawa; K Koide; N Morofuji; Y Hosokawa; K Shimomura; K Katsura; A Hagiwara; H Yamagishi; K Ito; Y Ito
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

4.  Association between H-RAS T81C genetic polymorphism and gastrointestinal cancer risk: a population based case-control study in China.

Authors:  Yongjing Zhang; Mingjuan Jin; Bing Liu; Xinyuan Ma; Kaiyan Yao; Qilong Li; Kun Chen
Journal:  BMC Cancer       Date:  2008-09-10       Impact factor: 4.430

Review 5.  Role of New Anatomy, Biliopancreatic Reflux, and Helicobacter Pylori Status in Postgastrectomy Stump Cancer.

Authors:  Luigi Basso; Gaetano Gallo; Daniele Biacchi; Maria Vittoria Carati; Giuseppe Cavallaro; Luca Esposito; Andrea Giuliani; Luciano Izzo; Paolo Izzo; Antonietta Lamazza; Andrea Polistena; Mariarita Tarallo; Alessandro Micarelli; Enrico Fiori
Journal:  J Clin Med       Date:  2022-03-09       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.